Erratum to: Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Applied Health Economics and Health Policy

• Publication date

  2012-12-12

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1007/s40258-013-0015-3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost Effectiveness of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder

  2012cited by this paper
• Pharmacological Interventions for the Treatment of Smokeless Tobacco Use

  2012cited by this paper
• Comparative effectiveness research using matching‐adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention‐deficit/hyperactivity disorder and comorbid oppositional defiant disorder

  2012cited by this paper
• Comparative Effectiveness Without Head-to-Head Trials

  2012cited by this paper
• Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research.

  2012cited by this paper
• Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States.

  2012cited by this paper
• Comparative Efficacy of Vildagliptin and Sitagliptin in Japanese Patients with Type 2 Diabetes Mellitus

  2011cited by this paper
• Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

  2011cited by this paper
• Long-Term Safety and Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

  2009cited by this paper
• Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study.

  2009cited by this paper
• Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.

  2009cited by this paper
• Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK

  2009cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

  2008cited by this paper
• Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents with ADHD

  2008cited by this paper
• Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

  2008cited by this paper
• Health state utilities for metastatic breast cancer

  2006cited by this paper
• A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

  2006cited by this paper
• Managing the cognitive effects of brain tumor radiation therapy

  2006cited by this paper
• Cost-effectiveness as an outcome in randomized clinical trials

  2006cited by this paper
• Comparative effectiveness: asking the right questions, choosing the right method.

  2005cited by this paper
• Effects of Atomoxetine on Growth After 2-Year Treatment Among Pediatric Patients With Attention-Deficit/Hyperactivity Disorder

  2005cited by this paper
• Efficacy and safety of atomoxetine in childhood Attention-Deficit/Hyperactivity Disorder with comorbid Oppositional Defiant Disorder

  2004cited by this paper
• Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

  2004cited by this paper
• Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study

  2002cited by this paper
• Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

  2002cited by this paper
• Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.

  2001cited by this paper
• Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder.

  2001cited by this paper
• Methylphenidate in children with hyperactivity: review and cost–utility analysis

  2001cited by this paper
• An Open-Label, Dose-Ranging Study of Atomoxetine in Children with Attention Deficit Hyperactivity Disorder

  2001cited by this paper
• Economic Evaluation of Oral Sumatriptan Compared with Oral Caffeine/Ergotamine for Migraine

  1997cited by this paper
• An Introduction to the Bootstrap

  1995cited by this paper
• Parasite screening and treatment among Indochinese refugees. Cost-benefit/utility and the General Health Policy Model.

  1985cited by this paper

• Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-ad

  2020cites this paper
• Matching‐adjusted indirect comparison of efficacy in patients with moderate‐to‐severe plaque psoriasis treated with ixekizumab vs. secukinumab

  2018cites this paper
• Evaluating Matching‐Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention‐Deficit/Hyperactivity Disorder

  2017cites this paper
• Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.

  2016cites this paper
• Pharmacological treatment of attention-deficit/hyperactivity disorder: assessing outcomes

  2015cites this paper
• The Potential for Misuse and Abuse of Medications in ADHD: A Review

  2014cites this paper
• Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison”

  2013cites this paper
• Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison

  2013cites this paper
• The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review

  2013cites this paper